Evidence map›Paper›PMID 36353186›Full record

ArticleJournal of market access & health policy2022

Barriers in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence Scenario.

Flavia A Duarte, Carlos Gil Ferreira, Rodrigo Dienstmann, Bruno L Ferrari, Matheus Costa E Silva, Pedro Nazareth A Junior, Paulo Guilherme de O Salles, Paulo Henrique C Diniz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of market access & health policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Flavia A DuarteOncology Department, Oncoclínicas do Brasil, Belo Horizonte, Brazil.ORCID https://orcid.org/0000-0002-4647-9788
Carlos Gil FerreiraOncology Department, Oncoclínicas Institute, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0002-7228-7018
Rodrigo DienstmannPrecision Medicine and Big Data Department, Oncoclínicas Group, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-5997-318X
Bruno L FerrariOncology Department, Oncoclínicas do Brasil, Belo Horizonte, Brazil.
Matheus Costa E SilvaPrecision Medicine and Big Data Department, Oncoclínicas Group, São Paulo, Brazil.
Pedro Nazareth A JuniorPrecision Medicine and Big Data Department, Oncoclínicas Group, São Paulo, Brazil.
Paulo Guilherme de O SallesPathology Department, Roberto Alvarenga Institute, Belo Horizonte, Brazil.ORCID https://orcid.org/0000-0001-8839-3491
Paulo Henrique C DinizOncology Department, Oncoclínicas do Brasil, Belo Horizonte, Brazil.ORCID https://orcid.org/0000-0003-2016-5593

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Precision oncology has a prominent role in nonsquamous non-small cell lung cancer (nsNSCLC) treatment progress; however, its access in a real-world scenario might be limited. Objective: To investigate the time spent in nsNSCLC molecular profile evaluation and its influence on clinical decisions. Methods: nsNSCLC patients who underwent molecular testing in a private referral Brazilian center between November 2015 and February 2020 were identified. The interval from nsNSCLC diagnosis to the characterization of the molecular profile was determined. Other outcomes, focusing on the biomarker tissue journey, were also assessed. Results: In this cohort ( Conclusions: Our data show a long median time from advanced nsNSCLC diagnosis and the availability of the biomarker testing in medical practice, which impacted the choice of a non-personalized therapy as the first-line.

Indexed as

drug accessnon-small cell lung cancerPrecision medicine

Identifiers

PMID36353186
PMCPMC9639562
OpenAlexW4281483995

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.